Ashley Teraishi

Ashley Teraishi

Auto-generated profile, based on publicly available information

Ashley Teraishi

UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles , Los Angeles, CA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2024 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
NCNicholas S Cho
Nicholas S Cho
FSFrancesco Sanvito
Francesco Sanvito
VLViên Lam Le
Viên Lam Le
SOSonoko Oshima
Sonoko Oshima
ATAshley Teraishi
Ashley Teraishi
BEBenjamin M. Ellingson
Benjamin M. Ellingson
BACKGROUND AND PURPOSE: The T2-FLAIR mismatch sign on MR imaging is a highly specific imaging biomarker of isocitrate dehydrogenase (IDH)-mutant astrocytomas, which lack 1p/19q codeletion. However, most studies using the T2-FLAIR mismatch sign have used visual assessment. This study quantified the degree of T2-FLAIR mismatch using digital subtraction of fluid-nulled T2-weighted FLAIR images from non-fluid-nulled T2-weighted images in human nonenhancing diffuse gliomas and then used this information to assess improvements in diagnostic performance and investigate subregion characteristics within these lesions. MATERIALS AND METHODS: Two cohorts of treatment-naïve, nonenhancing gliomas with known IDH and 1p/19q status were studied (n = 71 from The Cancer Imaging Archive (TCIA) and n = 34 in the institutional cohort). 3D volumes of interest corresponding to the tumor were segmented, and digital subtraction maps of T2-weighted MR imaging minus T2-weighted FLAIR MR imaging were used to partition each volume of interest into a T2-FLAIR mismatched subregion (T2-FLAIR mismatch, corresponding to voxels with positive values on the subtraction maps) and nonmismatched subregion (T2-FLAIR nonmismatch corresponding to voxels with negative values on the subtraction maps). Tumor subregion volumes, percentage of T2-FLAIR mismatch volume, and T2-FLAIR nonmismatch subregion thickness were calculated, and 2 radiologists assessed the T2-FLAIR mismatch sign with and without the aid of T2-FLAIR subtraction maps. RESULTS: Thresholds of ≥42% T2-FLAIR mismatch volume classified IDH-mutant astrocytoma with a specificity/sensitivity of 100%/19.6% (TCIA) and 100%/31.6% (institutional); ≥25% T2-FLAIR mismatch volume showed 92.0%/32.6% and 100%/63.2% specificity/sensitivity, and ≥15% T2-FLAIR mismatch volume showed 88.0%/39.1% and 93.3%/79.0% specificity/sensitivity. In IDH-mutant astrocytomas with ≥15% T2-FLAIR mismatch volume, T2-FLAIR nonmismatch subregion thickness was negatively correlated with the percentage T2-FLAIR mismatch volume (P < .0001) across both cohorts. The percentage T2-FLAIR mismatch volume was higher in grades 3–4 compared with grade 2 IDH-mutant astrocytomas (P < .05), and ≥15% T2-FLAIR mismatch volume IDH-mutant astrocytomas were significantly larger than <15% T2-FLAIR mismatch volume IDH-mutant astrocytoma (P < .05) across both cohorts. When evaluated by 2 radiologists, the additional use of T2-FLAIR subtraction maps did not show a significant difference in interreader agreement, sensitivity, or specificity compared with a separate evaluation of T2-FLAIR and T2-weighted MR imaging alone. CONCLUSIONS: T2-FLAIR digital subtraction maps may be a useful, automated tool to obtain objective segmentations of tumor subregions based on quantitative thresholds for classifying IDH-mutant astrocytomas using the percentage T2 FLAIR mismatch volume with 100% specificity and exploring T2-FLAIR mismatch/T2-FLAIR nonmismatch subregion characteristics. Conversely, the addition of T2-FLAIR subtraction maps did not enhance the sensitivity or specificity of the visual T2-FLAIR mismatch sign assessment by experienced radiologists.

28 August 2025 in Neuro-Oncology
Verified
Journal Article
Closed access
NCNicholas S Cho
Nicholas S Cho
VLViên Lam Le
Viên Lam Le
ATAshley Teraishi
Ashley Teraishi
VLVicki Liu
Vicki Liu
FSFrancesco Sanvito
Francesco Sanvito
BEBenjamin M. Ellingson
Benjamin M. Ellingson
Background: This study explored MRI characteristics at the time of tumor progression to study pathologically confirmed MT in IDHm 1p/19q-intact astrocytomas (IDHm-A) and IDHm 1p/19q-co-deleted oligodendrogliomas (IDHm-O). Methods: N = 64 patients with initial pathological grade 2 IDH-mutant glioma diagnosis who underwent repeated tissue sampling and were classified as pathologically confirmed MT (n = 35) or non-MT (n = 29) with available presurgical anatomical (n = 64), diffusion-weighted (n = 61), and dynamic susceptibility contrast perfusion MRI (n = 53) were retrospectively studied. Measurable contrast enhancement (> 1000 mm3), tumor volume, tumor growth rate, sphericity, median apparent diffusion coefficient (ADC), and normalized relative cerebral blood volume (nrCBV) were compared between MT vs non-MT IDHm-A and IDHm-O. Results: 81% of contrast-enhancing IDHm-A and 100% of contrast-enhancing IDHm-O demonstrated MT, while 41% of IDHm-A and 62% IDHm-O exhibited both nonenhancing tumor progression and MT. Tumor volumes were significantly larger in patients with MT compared to non-MT groups for IDHm-A (P = .02) and IDHm-O (P = .04). T2/FLAIR tumor volume growth rate was significantly higher (P = .003), nrCBV was significantly higher (P = .002), and ADC trended lower (P = .06) in MT vs non-MT IDHm-A. There were no significant differences in growth rate, ADC, nrCBV, or sphericity when comparing MT vs non-MT IDHm-O (P > .05). Conclusions: Many MT IDHm gliomas remain nonenhancing. Growth rate, diffusion, and perfusion MRI show differences between MT and non-MT in IDHm-A but not IDHm-O, which may reflect the different tumor biology of these IDHm molecular subtypes and their need for separate imaging biomarkers. Tumor volumes can help determine MT for both IDHm-A and IDHm-O.

14 May 2026 in Neuro-Oncology Practice
Verified
Journal Article
Open access
ATAshley Teraishi
Ashley Teraishi
FSFrancesco Sanvito
Francesco Sanvito
CRCatalina Raymond
Catalina Raymond
NCNicholas S Cho
Nicholas S Cho
JNJason Norris
Jason Norris
BEBenjamin M. Ellingson
Benjamin M. Ellingson
The clinical management of patients with brain tumors, as well as the results of clinical trials testing new medications, require the evaluation of tumor changes on MR imaging. After tumor measurements are obtained, the AIRES software application can automatically apply the standardized RANO rules, to ultimately define when the tumor can be considered in a progression phase, as opposed to a stable phase, or in treatment response. This automated tool enables fast, reliable, and reproducible assessments, and therefore has the potential to reduce errors, streamline workflows, and lower costs by minimizing the resources required for training personnel and conducting reads. The standardized Response Assessment in Neuro-Oncology (RANO), modified RANO (mRANO), and RANO 2.0 criteria are utilized for imaging endpoints in glioblastoma clinical trials. After measuring tumor size at each timepoint, the crucial step of categorizing progression, stable disease, and response based on numerical thresholds is currently done manually. “Manual” RANO evaluations are time-consuming, error prone, and require dedicated training. Here, we present the features, installation, and usage of Automated Imaging Response Evaluation System (AIRES), a software application prototype that applies mRANO criteria using externally measured tumor sizes, clinical status, and corticosteroid dose. AIRES labels each timepoint with RANO categories and calculates progression-free survival and objective response rate. As a real-world application on clinical trial datasets, mRANO reads were performed on measurements from 367 brain MRI scans across 41 patients from NUTMEG (NCT04195139), a phase II multicenter clinical trial. Four readers with varying levels of experience achieved a percentage of fully correct RANO reads ranging from 49% to 76%, while AIRES reached 100%, compared to a fifth expert reader. AIRES-based reads were significantly faster than “manual” reads by the expert (37.1 ± 8.6 vs 107.7 ± 58.6 s, P < .0001). AIRES is a reliable and time-efficient tool for mRANO assessments and may be adapted for RANO 2.0.

21 February 2026 in Radiology Case Reports
Verified
Journal Article
Open access
OIOmar Ibrahim
Omar Ibrahim
NCNicholas S Cho
Nicholas S Cho
VLViên Lam Le
Viên Lam Le
FSFrancesco Sanvito
Francesco Sanvito
JYJingwen Yao
Jingwen Yao
BEBenjamin M. Ellingson
Benjamin M. Ellingson
We present a rare case of concurrent, spatially distinct 1p/19q-intact IDH-mutant astrocytoma and 1p/19q-codeleted IDH-mutant oligodendroglioma in the same patient with divergent responses to IDH inhibitor therapy. A 40-year-old male presented to the emergency room following a seizure and was found to have 2 distinct left hemisphere tumors. Both lesions underwent biopsy and resection, with updated molecular diagnosis 4 years later revealing IDH-mutant 1p/19q-intact astrocytoma and IDH-mutant 1p/19q-codeleted oligodendroglioma. Tumor volumes, T2-FLAIR mismatch percentage, and normalized apparent diffusion coefficient (nADC) were quantified from serial MRIs. At initial presentation, quantitative analysis revealed the posterior lesion (IDH-mutant 1p/19q-intact astrocytoma) exhibited 60.6% T2-FLAIR mismatch volume and elevated median nADC of 2.72, while the anterior lesion (IDH-mutant 1p/19q-codeleted oligodendroglioma) showed minimal T2-FLAIR mismatch (1.8%) and lower median nADC (1.94). Volumetric analysis during IDH inhibitor (ivosidenib) therapy revealed differential response: the oligodendroglioma decreased in volume by 32.6% over 19 months, while the astrocytoma demonstrated progressive growth with a 77.3% volume increase over 19 months. This case demonstrates the utility of quantitative neuroimaging for accurate characterization of concurrent IDH-mutant gliomas with distinct molecular profiles. The observed differential response to IDH inhibition supports emerging evidence of molecular subtype-specific treatment sensitivities in IDH-mutant gliomas.